Alnylam Pharmaceuticals, Inc. (ALNY)
ALNY Stock Price Chart
Explore Alnylam Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze ALNY price movements and trends.
ALNY Company Profile
Discover essential business fundamentals and corporate details for Alnylam Pharmaceuticals, Inc. (ALNY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Jun 2004
Employees
2.23K
Website
https://www.alnylam.comCEO
Yvonne L. Greenstreet
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
ALNY Financial Timeline
Browse a chronological timeline of Alnylam Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 12 Jan 2026
Upcoming earnings on 30 Oct 2025
EPS estimate is $1.39, while revenue estimate is $938.88M.
Earnings released on 31 Jul 2025
EPS came in at $0.32 surpassing the estimated -$0.54 by +158.85%, while revenue for the quarter reached $773.69M , beating expectations by +16.72%.
Earnings released on 1 May 2025
EPS came in at -$0.01 surpassing the estimated -$0.89 by +98.88%, while revenue for the quarter reached $594.19M , beating expectations by +1.55%.
Earnings released on 13 Feb 2025
EPS came in at $0.06 surpassing the estimated -$0.62 by +109.68%, while revenue for the quarter reached $593.17M , beating expectations by +1.81%.
Earnings released on 31 Oct 2024
EPS came in at -$0.50 surpassing the estimated -$0.92 by +45.45%, while revenue for the quarter reached $500.92M , missing expectations by -6.00%.
Earnings released on 1 Aug 2024
EPS came in at $0.56 surpassing the estimated -$1.07 by +152.34%, while revenue for the quarter reached $659.83M , beating expectations by +47.54%.
Earnings released on 2 May 2024
EPS came in at -$0.16 surpassing the estimated -$1.12 by +85.71%, while revenue for the quarter reached $494.33M , beating expectations by +15.50%.
Earnings released on 15 Feb 2024
EPS came in at -$1.10 surpassing the estimated -$1.20 by +8.33%, while revenue for the quarter reached $439.72M , missing expectations by -0.72%.
Earnings released on 2 Nov 2023
EPS came in at $1.15 surpassing the estimated -$1.34 by +185.82%, while revenue for the quarter reached $750.53M , beating expectations by +87.15%.
Earnings released on 3 Aug 2023
EPS came in at -$2.21 falling short of the estimated -$1.72 by -28.49%, while revenue for the quarter reached $318.75M , missing expectations by -9.06%.
Earnings released on 4 May 2023
EPS came in at -$1.40 surpassing the estimated -$1.97 by +28.93%, while revenue for the quarter reached $319.29M , beating expectations by +2.25%.
Earnings released on 23 Feb 2023
EPS came in at -$1.68 surpassing the estimated -$2.13 by +21.13%, while revenue for the quarter reached $335.04M , beating expectations by +6.99%.
Earnings released on 27 Oct 2022
EPS came in at -$3.32 falling short of the estimated -$1.86 by -78.49%, while revenue for the quarter reached $264.31M , missing expectations by -9.38%.
Earnings released on 28 Jul 2022
EPS came in at -$2.29 falling short of the estimated -$1.62 by -41.36%, while revenue for the quarter reached $224.82M , missing expectations by -12.03%.
Earnings released on 28 Apr 2022
EPS came in at -$2.00 falling short of the estimated -$1.93 by -3.63%, while revenue for the quarter reached $213.26M , missing expectations by -11.49%.
Earnings released on 10 Feb 2022
EPS came in at -$2.16 falling short of the estimated -$1.47 by -46.94%, while revenue for the quarter reached $258.54M , beating expectations by +10.67%.
Earnings released on 28 Oct 2021
EPS came in at -$1.72 falling short of the estimated -$1.51 by -13.91%, while revenue for the quarter reached $187.63M , missing expectations by -14.59%.
Earnings released on 3 Aug 2021
EPS came in at -$1.61 falling short of the estimated -$1.57 by -2.55%, while revenue for the quarter reached $220.55M , meeting expectations.
Earnings released on 29 Apr 2021
EPS came in at -$1.71 surpassing the estimated -$1.75 by +2.29%, while revenue for the quarter reached $177.57M , beating expectations by +5.04%.
Earnings released on 11 Feb 2021
EPS came in at -$2.09 falling short of the estimated -$1.93 by -8.29%, while revenue for the quarter reached $163.56M , beating expectations by +11.49%.
Earnings released on 5 Nov 2020
EPS came in at -$2.18 falling short of the estimated -$1.75 by -24.57%, while revenue for the quarter reached $125.85M , beating expectations by +31.33%.
ALNY Stock Performance
Access detailed ALNY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.